PDCD1 and cancer: Wang et al.81 proposed an MMP-2-sensitive anti-PD-L1 antibody (aPD-L1)/ICG-based nanoparticle (S-aPD-L1/ICG@NP) that counteracts drug resistance in cancer immunotherapy by blocking the PD-1/PD-L1 cascade (Figure 3A).